Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, if he will publish the cost-benefit analysis on the extent of the (a) improvements in clinical outcomes and (b) unit cost reductions anticipated to result from the proposed closure of congenital heart disease services at the Royal Brompton Hospital.

No decision has been made on the proposals made by NHS England in July 2016. The proposal for the Royal Brompton and Harefield Hospitals NHS Foundation Trust is to decommission as a level 1 provider, not to close the congenital heart disease (CHD) service.

NHS England has been working with expert clinicians, patients, and Trust executives since 2013 to devise and agree a new set of standards for the treatment of CHD. The aim of these standards is to secure the best outcomes for all patients, including:

- improved opportunities for survivors to lead better lives;

- tackling variation in services, particularly to ensure resilient 24-hour, seven days a week care; and

- improved patient experience.

NHS England will be analysing the feedback from consultation to inform the NHS England Board’s decision-making later.